<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1349" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1349/" /><meta name="ncbi_pagename" content="TFR2-Related Hereditary Hemochromatosis - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>TFR2-Related Hereditary Hemochromatosis - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="TFR2-Related Hereditary Hemochromatosis" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/02/15" /><meta name="citation_author" content="Marco De Gobbi" /><meta name="citation_author" content="Antonella Roetto" /><meta name="citation_pmid" content="20301523" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1349/" /><meta name="citation_keywords" content="Type 3 Hereditary Hemochromatosis" /><meta name="citation_keywords" content="Type 3 Hereditary Hemochromatosis" /><meta name="citation_keywords" content="Transferrin receptor protein 2" /><meta name="citation_keywords" content="TFR2" /><meta name="citation_keywords" content="TFR2-Related Hereditary Hemochromatosis" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="TFR2-Related Hereditary Hemochromatosis" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Marco De Gobbi" /><meta name="DC.Contributor" content="Antonella Roetto" /><meta name="DC.Date" content="2018/02/15" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1349/" /><meta name="description" content="TFR2-related hereditary hemochromatosis (TFR2-HHC) is characterized by increased intestinal iron absorption resulting in iron accumulation in the liver, heart, pancreas, and endocrine organs. Age of onset is earlier than in HFE-associated HHC. The majority of individuals present with signs and symptoms of iron overload in the third decade (e.g., weakness, fatigue, abdominal pain, hepatomegaly, arthritis, arthralgia, progressive increase in skin pigmentation). Others present as young adults with nonspecific symptoms and abnormal serum iron studies or as adults with abnormal serum iron studies and signs of organ involvement including cirrhosis, diabetes mellitus, and arthropathy." /><meta name="og:title" content="TFR2-Related Hereditary Hemochromatosis" /><meta name="og:type" content="book" /><meta name="og:description" content="TFR2-related hereditary hemochromatosis (TFR2-HHC) is characterized by increased intestinal iron absorption resulting in iron accumulation in the liver, heart, pancreas, and endocrine organs. Age of onset is earlier than in HFE-associated HHC. The majority of individuals present with signs and symptoms of iron overload in the third decade (e.g., weakness, fatigue, abdominal pain, hepatomegaly, arthritis, arthralgia, progressive increase in skin pigmentation). Others present as young adults with nonspecific symptoms and abnormal serum iron studies or as adults with abnormal serum iron studies and signs of organ involvement including cirrhosis, diabetes mellitus, and arthropathy." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1349/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/tfr2/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1349/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8AFAF2E04291D10000000000FC005F.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1349_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1349_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/tbc1d24-dis/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/tk2-mtddepl/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1349_"><span class="title" itemprop="name"><i>TFR2</i>-Related Hereditary Hemochromatosis</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: Type 3 Hereditary Hemochromatosis</div><p class="contrib-group"><span itemprop="author">Marco De Gobbi</span>, MD and <span itemprop="author">Antonella Roetto</span>, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1349_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1349_ai__"><div class="contrib half_rhythm"><span itemprop="author">Marco De Gobbi</span>, MD<div class="affiliation small">Professor of Internal Medicine<br />Department of Clinical and Biological Sciences<br />University of Torino<br />Azienda Ospedaliera San Luigi<br />Torino, Italy<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ti.otinu@ibboged-ocram" class="oemail">ti.otinu@ibboged-ocram</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Antonella Roetto</span>, PhD<div class="affiliation small">Department of Clinical and Biological Sciences<br />University of Torino<br />Azienda Ospedaliera San Luigi<br />Torino, Italy<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ti.otinu@otteor.allenotna" class="oemail">ti.otinu@otteor.allenotna</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">August 29, 2005</span>; Last Update: <span itemprop="dateModified">February 15, 2018</span>.</p><p><em>Estimated reading time: 20 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="tfr2.Summary" itemprop="description"><h2 id="_tfr2_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>TFR2</i>-related hereditary hemochromatosis (<i>TFR2</i>-HHC) is characterized by increased intestinal iron absorption resulting in iron accumulation in the liver, heart, pancreas, and endocrine organs. Age of onset is earlier than in <i>HFE</i>-associated HHC. The majority of individuals present with signs and symptoms of iron overload in the third decade (e.g., weakness, fatigue, abdominal pain, hepatomegaly, arthritis, arthralgia, progressive increase in skin pigmentation). Others present as young adults with nonspecific symptoms and abnormal serum iron studies or as adults with abnormal serum iron studies and signs of organ involvement including cirrhosis, diabetes mellitus, and arthropathy.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of <i>TFR2-</i>HHC is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>TFR2</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Removal of excess iron by routine phlebotomy to maintain serum ferritin concentration at 50 ng/mL or lower and transferrin-iron saturation below 50%; lifelong hormone replacement therapy for hypogonadism; gonadotropins for fertility/pregnancy; nonsteroidal anti-inflammatory drugs and joint replacement for arthropathy; routine treatment for cardiac failure, diabetes mellitus, and hepatic complications.</p><p><i>Prevention of primary manifestations:</i> Routine phlebotomy; see <i>Treatment of manifestations</i>.</p><p><i>Surveillance:</i> Monitoring serum ferritin concentration every three to four months once serum ferritin concentration is lower than 50 ng/mL.</p><p><i>Agents/circumstances to avoid:</i> Medicinal iron and nutritional supplements containing iron, excessive alcohol intake, vitamin C supplements, uncooked seafood.</p><p><i>Evaluation of relatives at risk:</i> If the pathogenic variants in the family are known, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of at-risk relatives to allow early diagnosis and treatment.</p></div><div><h4 class="inline">Genetic counseling.</h4><p><i>TFR2</i>-HHC is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Heterozygotes (carriers) are asymptomatic and do not have abnormalities of iron parameters. Carrier testing for at-risk family members and prenatal testing for pregnancies at increased risk are possible once both pathogenic variants in the family have been identified.</p></div></div><div id="tfr2.Diagnosis"><h2 id="_tfr2_Diagnosis_">Diagnosis</h2><p>An algorithm for the diagnosis of <i>TFR2</i>-related hereditary hemochromatosis (<i>TFR2</i>-HHC) has been developed (see <a class="figpopup" href="/books/NBK1349/figure/tfr2.F1/?report=objectonly" target="object" rid-figpopup="figtfr2F1" rid-ob="figobtfr2F1">Figure 1</a>). See also <a class="bk_pop" href="#tfr2.REF.bardoujacquet.2013.278">Bardou-Jacquet et al [2013]</a>, Brissot [2016], <a class="bk_pop" href="#tfr2.REF.powell.2016.706">Powell et al [2016]</a>, and <a class="bk_pop" href="#tfr2.REF.zoller.2016.364">Zoller &#x00026; Henninger [2016]</a>.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figtfr2F1" co-legend-rid="figlgndtfr2F1"><a href="/books/NBK1349/figure/tfr2.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figtfr2F1" rid-ob="figobtfr2F1"><img class="small-thumb" src="/books/NBK1349/bin/tfr2-Image001.gif" src-large="/books/NBK1349/bin/tfr2-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndtfr2F1"><h4 id="tfr2.F1"><a href="/books/NBK1349/figure/tfr2.F1/?report=objectonly" target="object" rid-ob="figobtfr2F1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Flowchart for diagnosis of <i>TFR2</i>-HCC </p></div></div><div id="tfr2.Suggestive_Findings"><h3>Suggestive Findings</h3><p><i>TFR2</i>-HHC <b>should be suspected</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with clinical features, symptoms, and laboratory features associated with iron overload in whom <a href="/books/n/gene/hemochromatosis/"><i>HFE</i>-associated hereditary hemochromatosis</a> has been excluded.</p><p><b>Clinical features and symptoms of iron overload</b></p><ul><li class="half_rhythm"><div>Weakness, chronic fatigue</div></li><li class="half_rhythm"><div>Abdominal pain</div></li><li class="half_rhythm"><div>Hepatomegaly</div></li><li class="half_rhythm"><div>Cirrhosis, hepatocellular carcinoma</div></li><li class="half_rhythm"><div>Diabetes mellitus</div></li><li class="half_rhythm"><div>Cardiomyopathy, ECG abnormalities (conduction disturbances)</div></li><li class="half_rhythm"><div>Hypogonadism (decreased libido and impotence in men, amenorrhea in women)</div></li><li class="half_rhythm"><div>Arthritis (especially if involving the metacarpophalangeal joint), arthralgia</div></li><li class="half_rhythm"><div>Progressive increase in skin pigmentation</div></li></ul><p><b>Laboratory features</b></p><ul><li class="half_rhythm"><div><b>Transferrin saturation</b> &#x0003e;45% (normal range: 20%-35% saturation in males and females)</div></li><li class="half_rhythm"><div><b>Serum ferritin concentration</b> usually &#x0003e;200 &#x000b5;g/L in females and &#x0003e;300 &#x000b5;g/L in males</div><div>Normal ranges:</div><ul><li class="half_rhythm"><div>Children and adolescents: 15-150 &#x000b5;g/L</div></li><li class="half_rhythm"><div>Adult females: 20-200 &#x000b5;g/L</div></li><li class="half_rhythm"><div>Adult males: 20-300 &#x000b5;g/L</div></li></ul></li><li class="half_rhythm"><div>Elevated liver enzymes and/or abnormal liver function tests</div></li><li class="half_rhythm"><div>Hyperglycemia</div></li></ul><p><b>Liver biopsy.</b> Findings on liver biopsy have been reported in some individuals with <i>TFR2</i>-HHC [<a class="bk_pop" href="#tfr2.REF.girelli.2002.1295">Girelli et al 2002</a>, <a class="bk_pop" href="#tfr2.REF.pietrangelo.2005.470">Pietrangelo et al 2005</a>, <a class="bk_pop" href="#tfr2.REF.hsiao.2007.303">Hsiao et al 2007</a>, <a class="bk_pop" href="#tfr2.REF.pelucchi.2009.276">Pelucchi et al 2009</a>, <a class="bk_pop" href="#tfr2.REF.del_castillorueda.2011.68">Del Castillo-Rueda et al 2011</a>, <a class="bk_pop" href="#tfr2.REF.hattori.2012.612">Hattori et al 2012</a>, <a class="bk_pop" href="#tfr2.REF.joshi.2015.221">Joshi et al 2015</a>, <a class="bk_pop" href="#tfr2.REF.badar.2016.420">Badar et al 2016</a>, <a class="bk_pop" href="#tfr2.REF.peters.2017.56">Peters at al 2017</a>]. Liver biopsy is used to assess:</p><ul><li class="half_rhythm"><div>Histology; fibrosis or cirrhosis</div></li><li class="half_rhythm"><div>Elevated liver iron concentration (normal values: 10-35 &#x000b5;mol/g dry liver weight or 0.56-1.96 mg/g dry liver weight):</div><ul><li class="half_rhythm"><div>Mild. 70-99 &#x000b5;mol/g dry liver weight or 3.9-5.5 mg/g dry liver weight</div></li><li class="half_rhythm"><div>Moderate. 100-200 &#x000b5;mol/g dry liver weight or 5.6-11.2 mg/g dry liver weight</div></li><li class="half_rhythm"><div>Severe. &#x0003e;200 &#x000b5;mol/g dry liver weight or &#x0003e;11.2 mg/g dry liver weight</div></li></ul></li></ul><p><b>Imaging.</b> Noninvasive techniques including MRI and SQUID developed to quantitate liver iron concentration have been applied to <i>TFR2</i>-HHC [<a class="bk_pop" href="#tfr2.REF.biasiotto.2008.309">Biasiotto et al 2008</a>, <a class="bk_pop" href="#tfr2.REF.pelucchi.2009.276">Pelucchi et al 2009</a>, <a class="bk_pop" href="#tfr2.REF.ricerca.2009.494">Ricerca et al 2009</a>, <a class="bk_pop" href="#tfr2.REF.del_castillorueda.2011.68">Del Castillo-Rueda et al 2011</a>, <a class="bk_pop" href="#tfr2.REF.delcastillorueda.2012.15">Del-Castillo-Rueda et al 2012</a>, <a class="bk_pop" href="#tfr2.REF.joshi.2015.221">Joshi et al 2015</a>, <a class="bk_pop" href="#tfr2.REF.badar.2016.420">Badar et al 2016</a>].</p><p><b>Hepcidin evaluation.</b> Individuals with <i>TFR2</i>-HHC have decreased hepcidin concentrations in plasma and urine (similar to other types of <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> HHC). Hepcidin concentration in plasma and urine can be measured by mass-spectrometry-based assay and normalized for gender and age [<a class="bk_pop" href="#tfr2.REF.piubelli.2017.562">Piubelli et al 2017</a>].</p></div><div id="tfr2.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>No specific diagnostic guidelines are available for <i>TFR2</i>-HHC.</p><p>The diagnosis of <i>TFR2-</i>HHC <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>TFR2</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1349/table/tfr2.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figtfr2Tmoleculargenetictestingusedin" rid-ob="figobtfr2Tmoleculargenetictestingusedin">Table 1</a>).</p><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, and <b>more comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>TFR2</i> is performed first and followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>TFR2</i> and other genes of interest (see <a href="#tfr2.Differential_Diagnosis">Differential Diagnosis</a>) can be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>More comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or genes that results in a similar clinical presentation).</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="tfr2.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>TFR2</i>-Related Hereditary Hemochromatosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1349/table/tfr2.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tfr2.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tfr2.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_tfr2.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_tfr2.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_tfr2.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>TFR2</i></td><td headers="hd_h_tfr2.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_tfr2.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;99%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_tfr2.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_tfr2.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="tfr2.TF.1.1"><p class="no_margin">See <a href="/books/NBK1349/#tfr2.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="tfr2.TF.1.2"><p class="no_margin">See <a href="#tfr2.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants.</p></div></dd><dt>3. </dt><dd><div id="tfr2.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="tfr2.TF.1.4"><p class="no_margin"><a class="bk_pop" href="#tfr2.REF.mcdonald.2015.1288">McDonald et al [2015]</a>, <a class="bk_pop" href="#tfr2.REF.badar.2016.420">Badar et al [2016]</a>, <a class="bk_pop" href="#tfr2.REF.faria.2016.10">Faria et al [2016]</a>, <a class="bk_pop" href="#tfr2.REF.lanktree.2017.228">Lanktree et al [2017]</a>, <a class="bk_pop" href="#tfr2.REF.peters.2017.56">Peters et al [2017]</a></p></div></dd><dt>5. </dt><dd><div id="tfr2.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="tfr2.TF.1.6"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available.</p></div></dd></dl></div></div></div></div></div><div id="tfr2.Clinical_Characteristics"><h2 id="_tfr2_Clinical_Characteristics_">Clinical Characteristics</h2><div id="tfr2.Clinical_Description"><h3>Clinical Description</h3><p><i>TFR2</i>-related hereditary hemochromatosis (<i>TFR2</i>-HHC) is characterized by deregulated, increased intestinal iron absorption resulting in iron accumulation in the liver, heart, pancreas, and endocrine organs [<a class="bk_pop" href="#tfr2.REF.camaschella.2009.140">Camaschella &#x00026; Poggiali 2009</a>].</p><p><b>Age of onset</b> in individuals with <i>TFR2</i>-HHC is earlier than in individuals with <a href="/books/n/gene/hemochromatosis/"><i>HFE</i>-associated hereditary hemochromatosis</a>. Five individuals with childhood onset (range of onset: age 3-13 years) have been reported [<a class="bk_pop" href="#tfr2.REF.piperno.2004.359">Piperno et al 2004</a>, <a class="bk_pop" href="#tfr2.REF.biasiotto.2008.309">Biasiotto et al 2008</a>, <a class="bk_pop" href="#tfr2.REF.joshi.2015.221">Joshi et al 2015</a>, <a class="bk_pop" href="#tfr2.REF.ravasi.2015.e226">Ravasi et al 2015</a>], all with increased transferrin saturation and serum ferritin concentration. However, the majority of the individuals present with signs of iron overload from the third decade, as young adults with nonspecific symptoms and abnormal serum iron indices [<a class="bk_pop" href="#tfr2.REF.biasiotto.2008.309">Biasiotto et al 2008</a>, <a class="bk_pop" href="#tfr2.REF.g_rolami.2008.e45">G&#x000e9;rolami et al 2008</a>, <a class="bk_pop" href="#tfr2.REF.delcastillorueda.2012.15">Del-Castillo-Rueda et al 2012</a>, <a class="bk_pop" href="#tfr2.REF.peters.2017.56">Peters et al 2017</a>], or as adults with abnormal serum iron studies and signs of organ involvement (e.g., liver fibrosis or cirrhosis, diabetes, hypogonadism, arthropathy) [<a class="bk_pop" href="#tfr2.REF.pelucchi.2009.276">Pelucchi et al 2009</a>, <a class="bk_pop" href="#tfr2.REF.delcastillorueda.2012.15">Del-Castillo-Rueda et al 2012</a>, <a class="bk_pop" href="#tfr2.REF.hattori.2012.612">Hattori et al 2012</a>, <a class="bk_pop" href="#tfr2.REF.joshi.2015.221">Joshi et al 2015</a>, <a class="bk_pop" href="#tfr2.REF.badar.2016.420">Badar et al 2016</a>, <a class="bk_pop" href="#tfr2.REF.peters.2017.56">Peters et al 2017</a>, <a class="bk_pop" href="#tfr2.REF.wang.2017.521">Wang et al 2017</a>].</p><p><b>Disease progression</b> is slower than in <a href="/books/n/gene/jh/">juvenile hereditary hemochromatosis</a> [<a class="bk_pop" href="#tfr2.REF.de_gobbi.2002.973">De Gobbi et al 2002</a>].</p><p>When <i>TFR2</i>-HHC is progressive, complications can include cirrhosis and hypogonadotropic hypogonadism. Severe joint involvement has been reported [<a class="bk_pop" href="#tfr2.REF.ricerca.2009.494">Ricerca et al 2009</a>, <a class="bk_pop" href="#tfr2.REF.peters.2017.56">Peters et al 2017</a>]. Cardiomyopathy and diabetes mellitus are rare [<a class="bk_pop" href="#tfr2.REF.de_gobbi.2002.973">De Gobbi et al 2002</a>, <a class="bk_pop" href="#tfr2.REF.riva.2004.370">Riva et al 2004</a>]. While the distribution of liver iron deposition is similar to that seen in <a href="/books/n/gene/hemochromatosis/"><i>HFE</i>-associated hereditary hemochromatosis</a> (mainly in hepatocytes with a decreasing gradient from portal to centrolobular areas), hepatocellular carcinoma (HCC) has not been observed in the limited number of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals reported to date. Even in a large series of individuals with HCC, the subgroup with increased liver iron concentration did not have <i>TFR2</i> pathogenic variants [<a class="bk_pop" href="#tfr2.REF.funakoshi.2016.746">Funakoshi et al 2016</a>].</p><p>If <i>TFR2</i>-HHC is diagnosed early and treated appropriately with phlebotomy, individuals with <i>TFR2</i>-HHC will have normal life expectancy. Similar to <i>HFE</i>-associated hereditary hemochromatosis, the most important factors that can influence survival are the onset of cirrhosis, diabetes, and/or cardiomyopathy. The oldest individual to be diagnosed with <i>TFR2</i>-HHC is an Italian individual diagnosed at age 82 years [<a class="bk_pop" href="#tfr2.REF.roetto.2001.2555">Roetto et al 2001</a>].</p></div><div id="tfr2.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>The limited number of individuals reported and the <a class="def" href="/books/n/gene/glossary/def-item/private/">private</a> nature of the pathogenic variants do not permit <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a>.</p><p>Inheritance of compound heterozygosity for the <i>HFE</i> pathogenic variants p.Cys282Tyr (<a href="/protein/NP_000401.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000401.1</a>; <a href="/nuccore/NM_000410.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000410.3</a>:c. 845G&#x0003e;A) and p.His63Asp and homozygosity for the <i>TFR2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK1349/table/tfr2.T.tfr2_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figtfr2Ttfr2pathogenicvariantsdiscusse" rid-ob="figobtfr2Ttfr2pathogenicvariantsdiscusse">p.Gln317Ter</a> produced a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of juvenile hemochromatosis in a single family [<a class="bk_pop" href="#tfr2.REF.pietrangelo.2005.470">Pietrangelo et al 2005</a>].</p></div><div id="tfr2.Penetrance"><h3>Penetrance</h3><p>The <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of <i>TFR2</i>-HHC is less than 100% and can be influenced by environmental factors. In a family reported by <a class="bk_pop" href="#tfr2.REF.roetto.2001.2555">Roetto et al [2001]</a>, one middle-aged female <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the <i>TFR2</i>
<a class="figpopup" href="/books/NBK1349/table/tfr2.T.tfr2_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figtfr2Ttfr2pathogenicvariantsdiscusse" rid-ob="figobtfr2Ttfr2pathogenicvariantsdiscusse">p.Arg30ProfsTer31</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> had iron defiency and a history of low dietary iron intake and hypermenorrhea. <a class="bk_pop" href="#tfr2.REF.girelli.2002.1295">Girelli et al [2002]</a> also found iron deficiency in a young female homozygous for <a class="figpopup" href="/books/NBK1349/table/tfr2.T.tfr2_pathogenic_variants_discusse/?report=objectonly" target="object" rid-figpopup="figtfr2Ttfr2pathogenicvariantsdiscusse" rid-ob="figobtfr2Ttfr2pathogenicvariantsdiscusse">p.Ala621_Gln624del</a> who had a history of anorexia and <i>Helicobacter pylori</i>-related chronic gastritis.</p></div><div id="tfr2.Nomenclature"><h3>Nomenclature</h3><p><i>TFR2</i>-HHC is also known as hemochromatosis type 3 (HFE3); however, the term HFE3 seems inappropriate because <i>HFE</i> has no role in <i>TFR2</i>-HHC.</p></div><div id="tfr2.Prevalence"><h3>Prevalence</h3><p><i>TFR2</i>-HHC is rare, with pathogenic <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> frequencies estimated within the range of 0.000008 to 0.0002 [<a class="bk_pop" href="#tfr2.REF.wallace.2016.618">Wallace &#x00026; Subramaniam 2016</a>]. Approximately 50 <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have been reported worldwide, most commonly in Italy, Japan, and Portugal.</p><p>In Japan, where hemochromatosis is rare and heterogeneous, it has been proposed that <i>TFR2</i>-HHC is the most frequent form of hereditary hemochromatosis [<a class="bk_pop" href="#tfr2.REF.hayashi.2006.1107">Hayashi et al 2006</a>]; however, studies are limited.</p></div></div><div id="tfr2.Genetically_Related_Allelic_Disorde"><h2 id="_tfr2_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p>No other phenotypes are known to be associated with pathogenic variants in <i>TFR2</i>.</p></div><div id="tfr2.Differential_Diagnosis"><h2 id="_tfr2_Differential_Diagnosis_">Differential Diagnosis</h2><p><i>TFR2</i>-related hereditary hemochromatosis (<i>TFR2</i>-HHC) needs to be distinguished from other primary iron overload disorders as well as from secondary iron overload disorders (see <a class="figpopup" href="/books/NBK1349/figure/tfr2.F1/?report=objectonly" target="object" rid-figpopup="figtfr2F1" rid-ob="figobtfr2F1">Figure 1</a>). No specific studies have evaluated the percentage of <i>TFR2</i> pathogenic variants detected in individuals with non-<i>HFE</i>-associated hereditary hemochromatosis.</p><div id="tfr2.Primary_Iron_Overload_Disorders"><h3>Primary Iron Overload Disorders</h3><div id="tfr2.T.primary_iron_overload_disorders_t" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Primary Iron Overload Disorders to Consider in the Differential Diagnosis of <i>TFR2</i>-HHC</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1349/table/tfr2.T.primary_iron_overload_disorders_t/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tfr2.T.primary_iron_overload_disorders_t_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_1" style="text-align:left;vertical-align:middle;">Disorder&#x000a0;<sup>1</sup></th><th id="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Clinical Features of This Disorder</th></tr><tr><th headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_4" id="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping with <i>TFR2</i>-HHC</th><th headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_4" id="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from <i>TRF2</i>-HHC</th></tr></thead><tbody><tr><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/hemochromatosis/"><i>HFE</i>-related hereditary hemochromatosis</a></td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HFE</i></td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_4 hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Biochemical &#x00026; clinical features of iron overload</td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_4 hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Lower <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a></div></li><li class="half_rhythm"><div>Later onset</div></li></ul>
</td></tr><tr><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/jh/">Juvenile hereditary hemochromatosis</a></td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>HJV</i><br /><i>HAMP</i></td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_4 hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Biochemical &#x00026; clinical features of iron overload</td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_4 hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Full <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a></div></li><li class="half_rhythm"><div>Earlier onset</div></li><li class="half_rhythm"><div>More severe clinical manifestations, esp cardiomyopathy &#x00026; hypogonadism</div></li></ul>
</td></tr><tr><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ferroportin 1-associated hemochromatosis (OMIM <a href="http://omim.org/entry/606069" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">606069</a>)</td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC40A1</i></td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_4 hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Biochemical &#x00026; clinical features of iron overload</td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_4 hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Later-onset clinical manifestations of iron overload</td></tr><tr><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ferroportin disease&#x000a0;<sup>2</sup></td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC40A1</i></td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_4 hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hyperferritinemia</td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_4 hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>At early stage: anemia &#x00026; low transferrin saturation</div></li><li class="half_rhythm"><div>Iron deposition in hepatic reticuloendothelial (not parenchymal) cells</div></li><li class="half_rhythm"><div>Reduced tolerance to phlebotomy</div></li></ul>
</td></tr><tr><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/acp/">Aceruloplasminemia</a></td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CP</i></td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_4 hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Hyperferritinemia</div></li><li class="half_rhythm"><div>Diabetes mellitus</div></li></ul>
</td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_4 hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Anemia</div></li><li class="half_rhythm"><div>Iron deposition in hepatic reticuloendothelial (not parenchymal) cells</div></li><li class="half_rhythm"><div>Brain iron accumulation manifesting as retinal degeneration &#x00026; neurologic disease (movement disorders &#x00026; ataxia)</div></li></ul>
</td></tr><tr><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">African iron overload (OMIM <a href="http://omim.org/entry/601195" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">601195</a>)</td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_4 hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Liver iron accumulation in reticuloendothelial &#x00026; parenchymal cells</div></li><li class="half_rhythm"><div>Cirrhosis</div></li></ul>
</td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_4 hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>In drinkers of beer brewed in non-galvanized steel drums</div></li><li class="half_rhythm"><div>Lower frequency of cardiomyopathy &#x00026; diabetes</div></li><li class="half_rhythm"><div>Susceptibility to tuberculosis &#x00026; other infections</div></li></ul>
</td></tr><tr><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neonatal hemochromatosis (<a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> alloimmune hepatitis)<br />(OMIM <a href="http://omim.org/entry/231100" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">231100</a>)</td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_4 hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Iron deposition in multiple organs (liver, pancreas, heart, endocrine glands)</td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_4 hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Alloimmune pathogenesis</div></li><li class="half_rhythm"><div>Iron overload in fetus</div></li><li class="half_rhythm"><div>Severe liver failure at birth, often fatal without liver transplant</div></li></ul>
</td></tr><tr><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bmp6-related iron overload<br />(OMIM <a href="http://omim.org/entry/112266" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">112266</a>)</td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>BMP6</i></td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_4 hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Biochemical features of iron overload</div></li><li class="half_rhythm"><div>Liver iron accumulation</div></li></ul>
</td><td headers="hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_1_4 hd_h_tfr2.T.primary_iron_overload_disorders_t_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Normal transferrin saturation in some</div></li><li class="half_rhythm"><div>Mild-to-moderate late onset of iron overload</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a></p></div></dd><dt>1. </dt><dd><div id="tfr2.TF.2.1"><p class="no_margin">Primary overload disorders are characterized by increased absorption of iron from a normal diet.</p></div></dd><dt>2. </dt><dd><div id="tfr2.TF.2.2"><p class="no_margin"><a class="bk_pop" href="#tfr2.REF.pietrangelo.2017.1972">Pietrangelo [2017]</a></p></div></dd></dl></div></div></div></div><div id="tfr2.Secondary_Iron_Overload_Disorders"><h3>Secondary Iron Overload Disorders</h3><p>Secondary iron overload disorders include iron excess resulting from different conditions. The most severe disorders result from transfusions for chronic anemia such as <a href="/books/n/gene/b-thal/">beta-thalassemia</a> or <a href="/books/n/gene/sickle/">sickle cell disease</a>. Secondary iron overload may result from ingested iron in foods, cookware, and medicines, as well as parenteral iron from iron injections.</p><p>This group also includes a range of liver diseases associated with parenchymal liver disease (e.g., alcoholic liver disease, acute viral hepatitis or chronic hepatitis C, neoplasia, <a href="/books/n/gene/porphyria-ct/">porphyria cutanea tarda</a>) and inflammatory disorders such as rheumatoid arthritis (which are questionable because inflammatory disorders are not true iron-loading disorders).</p><p>See Hemochromatosis: <a href="https://www.omim.org/phenotypicSeries/PS235200" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM Phenotypic Series</a> to view genes associated with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in OMIM.</p></div></div><div id="tfr2.Management"><h2 id="_tfr2_Management_">Management</h2><div id="tfr2.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with <i>TFR2</i>-related hereditary hemochromatosis (<i>TFR2</i>-HHC), the following are recommended (based on recommendations for <a href="/books/n/gene/hemochromatosis/"><i>HFE</i>-associated hereditary hemochromatosis</a>) if they have not already been completed:</p><ul><li class="half_rhythm"><div>Liver biopsy for evaluation of abnormal liver function tests and establishing prognosis when serum ferritin concentration is greater than 1,000 ng/mL, especially if there is an underlying liver disease (e.g., alcohol abuse, viral hepatitis)</div></li><li class="half_rhythm"><div>Liver elastography for detecting hepatic fibrosis</div></li><li class="half_rhythm"><div>Serum concentration of gonadotropins (FSH and LH) to assess pituitary function at time of diagnosis of iron overload. Depending on the results, a GnRH stimulation test may be necessary.</div></li><li class="half_rhythm"><div>Serum concentration of testosterone to assess testicular function and serum concentration of estradiol to assess ovarian function at time of diagnosis of iron overload</div></li><li class="half_rhythm"><div>Radiographs of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> joint(s) to assess persistent arthralgia or arthropathy</div></li><li class="half_rhythm"><div>Cardiac evaluation (ECG and echocardiography) for all symptomatic individuals and those with severe iron overload (ferritin &#x0003e;1,000 ng/mL)</div></li><li class="half_rhythm"><div>Screening for diabetes mellitus by fasting serum glucose concentration and oral glucose tolerance test at time of diagnosis of iron overload</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="tfr2.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Since individuals with increased serum ferritin concentration should be treated by the same protocol as for <i>HFE</i>-associated hereditary hemochromatosis, the following recommendations are mainly based on guidelines proposed for <a href="/books/n/gene/hemochromatosis/"><i>HFE</i>-associated hereditary hemochromatosis</a> in Europe [<a class="bk_pop" href="#tfr2.REF.european_association_for_the_study_of_the_liver.2010.3">European Association for the Study of the Liver 2010</a>] (<a href="http://www.sciencedirect.com/science/article/pii/S0168827810001972" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>) and North America [<a class="bk_pop" href="#tfr2.REF.bacon.2011.328">Bacon et al 2011</a>] (<a href="http://onlinelibrary.wiley.com/doi/10.1002/hep.24330/epdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>). However, it should be emphasized that since <i>TFR2</i>-HHC is rare and may progress differently from <i>HFE</i>-associated hemochromatosis, individual treatment is important.</p><div id="tfr2.Therapeutic_Phlebotomy"><h4>Therapeutic Phlebotomy</h4><p>Periodic phlebotomy (i.e., removal of a unit of blood) is a simple, inexpensive, safe, and effective way to remove excess iron. Each unit of blood (400-500 mL) with a hematocrit of 40% contains approximately 160-200 mg of iron.</p><p>The usual therapy is phlebotomy weekly or every two weeks; however, twice-weekly phlebotomy or erythrocytapheresis may be useful initially to accelerate iron depletion. Hematocrit or hemoglobin level should be checked prior to each phlebotomy. In the initial stage of treatment, when serum ferritin is high, ferritin measurement should be performed approximately every ten phlebotomies.</p><p>Weekly phlebotomy is carried out until the serum ferritin concentration is 50 ng/mL or lower. If anemia is detected or hematocrit is reduced from the initial level by more than 20%, phlebotomy should be postponed.</p><p>As the target range of 50-100 ng/mL is approached, serum ferritin analysis may be repeated more frequently.</p><p>Note: Although experience is limited because of the small number of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals identified worldwide, it should be noted that transferrin saturation remains high in <i>TFR2</i>-related hereditary hemochromatosis when serum ferritin concentration is low (&#x0003c;50 ng/mL), even after intensive phlebotomy [<a class="bk_pop" href="#tfr2.REF.girelli.2011.500">Girelli et al 2011</a>; Camaschella, Roetto, &#x00026; De Gobbi, unpublished observations].</p><p><b>Maintenance therapy.</b> The goal is to maintain serum ferritin concentration around 50 ng/mL and transferrin-iron saturation below 50%. Phlebotomy to prevent reaccumulation of iron is performed about every three to four months. However, the frequency of maintenance therapy varies by individual.</p><p><b>Iron chelation therapy</b> is not recommended unless an individual has an elevated serum ferritin concentration and concomitant anemia or cardiac dysfunction that makes therapeutic phlebotomy impossible. Subcutaneous desferrioxamine has been used in individuals with concomitant anemia alone [<a class="bk_pop" href="#tfr2.REF.riva.2004.370">Riva et al 2004</a>] or in combination with deferiprone [<a class="bk_pop" href="#tfr2.REF.tauchenov_.2016.1574.e1">Tauchenov&#x000e1; et al 2016</a>]. A Phase I/II trial with the oral chelator deferasirox demonstrated that this treatment is feasible, safe, and effective &#x02013; although associated with a high incidence of gastrointestinal side effects [<a class="bk_pop" href="#tfr2.REF.phatak.2010.1671">Phatak et al 2010</a>].</p></div><div id="tfr2.Treatment_of_Clinical_Complications"><h4>Treatment of Clinical Complications</h4><p><b>Cirrhosis</b> should be treated and followed up as in other conditions. Although cirrhosis is not reversible by phlebotomy, individuals with cirrhosis benefit from iron removal in that it reduces the risk of hepatocellular cancer.</p><p><b>Hypogonadism</b> is irreversible and requires lifelong hormone replacement therapy in males and females. Use of gonadotropins has successfully restored fertility and induced pregnancy in women who have been treated for other forms of hemochromatosis.</p><p><b>Arthropathy</b> requires nonsteroidal anti-inflammatory drugs and is barely influenced by phlebotomy. In some individuals, joint replacement has been performed.</p><p><b>Cardiac failure</b> is treated with diuretics, ACE inhibitors, cardiac glycosides, and iron chelation by intravenous or subcutaneous desferrioxamine.</p><p><b>Diabetes mellitus</b> may require lifelong insulin treatment. Iron removal may improve control of diabetes mellitus but cannot reestablish normal glucose metabolism.</p></div></div><div id="tfr2.Prevention_of_Primary_Manifestation"><h3>Prevention of Primary Manifestations</h3><p>In <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with increased serum ferritin concentration, prevention of primary manifestations is accomplished by weekly phlebotomy to deplete iron stores (see <a href="#tfr2.Treatment_of_Manifestations">Treatment of Manifestations</a>).</p></div><div id="tfr2.Surveillance"><h3>Surveillance</h3><p>As with <a href="#tfr2.Treatment_of_Manifestations">treatment</a>, the surveillance of <i>TFR2-</i>HHC is based on guidelines proposed for <a href="/books/n/gene/hemochromatosis/"><i>HFE</i>-associated hereditary hemochromatosis</a> in Europe [<a class="bk_pop" href="#tfr2.REF.european_association_for_the_study_of_the_liver.2010.3">European Association for the Study of the Liver 2010</a>] (<a href="http://www.sciencedirect.com/science/article/pii/S0168827810001972" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>) and North America [<a class="bk_pop" href="#tfr2.REF.bacon.2011.328">Bacon et al 2011</a>] (<a href="http://onlinelibrary.wiley.com/doi/10.1002/hep.24330/epdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p><p>Once the serum ferritin concentration is around 50 ng/mL, monitoring serum ferritin concentration every three to four months is adequate while continuing phlebotomies at intervals to keep ferritin at this level.</p><p>Although hepatocellular carcinoma has not been reported in individuals with <i>TFR2</i>-associated hereditary hemochromatosis, surveillance for its development should be performed in persons with cirrhosis by monitoring liver ultrasound examinations and serum concentrations of alpha-fetoprotein, as in persons with cirrhosis with <i>HFE</i>-associated hereditary hemochromatosis.</p></div><div id="tfr2.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Avoid the following:</p><ul><li class="half_rhythm"><div>Medicinal iron and nutritional supplements containing iron</div></li><li class="half_rhythm"><div>Excessive alcohol intake because it increases iron absorption and is toxic to the hepatocytes</div></li><li class="half_rhythm"><div>Vitamin C supplements because they may enhance iron absorption</div></li><li class="half_rhythm"><div>Uncooked seafood because of the risk of infection from microorganisms thriving under conditions of excess iron (e.g., <i>Yersinia enterocolitica</i>, <i>Vibrio vulnificus</i>)</div></li></ul></div><div id="tfr2.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>In order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures, it is appropriate to evaluate apparently asymptomatic older and younger sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of the <i>TFR2</i> pathogenic variants found in the family.</p><p>See <a href="#tfr2.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="tfr2.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Women with hemochromatosis do not need treatment during pregnancy because fetal utilization of maternal iron effectively reduces the mother's iron load during pregnancy.</p></div><div id="tfr2.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="tfr2.Genetic_Counseling"><h2 id="_tfr2_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="tfr2.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>TFR2</i>-related hereditary hemochromatosis (<i>TFR2</i>-HHC) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="tfr2.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are obligate heterozygotes (i.e., carriers of one <i>TFR2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic, do not have abnormalities of iron parameters, and are not at risk of developing the disorder [<a class="bk_pop" href="#tfr2.REF.roetto.2001.2555">Roetto et al 2001</a>].</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and do not have abnormalities of iron parameters.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with <i>TFR2</i>-HHC are obligate heterozygotes (carriers) for the given <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>TFR2</i>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>TFR2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="tfr2.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier detection using <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for at-risk family members is possible once the pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member.</p><p>Carrier detection using biochemical testing is not possible because iron parameters are normal in heterozygotes.</p></div><div id="tfr2.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#tfr2.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="tfr2.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>TRF2</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="tfr2.Resources"><h2 id="_tfr2_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>American Hemochromatosis Society, Inc.</b></div><div>P.O. Box 950871</div><div>Lake Mary FL 32795-0871</div><div><b>Phone:</b> 407-829-4488; 888-655-IRON (4766)</div><div><b>Fax:</b> 407-333-1284</div><div><b>Email:</b> mail@americanhs.org</div><div><a href="http://www.americanhs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.americanhs.org</a></div></li><li class="half_rhythm"><div><b>Canadian Hemochromatosis Society</b></div><div>7000 Minoru Boulevard</div><div>Suite 285</div><div>Richmond British Columbia V6Y 3Z5</div><div>Canada</div><div><b>Phone:</b> 877-BAD-IRON (1-877-223-4766); 604-279-7135</div><div><b>Email:</b> office@toomuchiron.ca</div><div><a href="https://www.toomuchiron.ca/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.toomuchiron.ca</a></div></li><li class="half_rhythm"><div><b>EFAPH: European Federation of Associations of Patients with Haemochromatosis</b></div><div>4 rue Paul Demange</div><div>Croissy-sur-Seine F-78290</div><div>France</div><div><b>Phone:</b> 00 33 (0)6 08 25 94 04</div><div><b>Email:</b> fcourtois.dom@wanadoo.fr; efaph@gmx.eu</div><div><a href="http://efaph.eu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.efaph.eu</a></div></li><li class="half_rhythm"><div><b>Haemochromatosis Society</b></div><div>Haemochromatosis UK Office</div><div>Henrith Business Centre, 3 Enterprise Way</div><div>Pinchbeck, Spalding Lincolnshire PE11 3YR</div><div>United Kingdom</div><div><b>Phone:</b> 03030 401 101; 03030 401 102</div><div><b>Email:</b> office@huk.org.uk; helpline@huk.org.uk</div><div><a href="http://haemochromatosis.org.uk/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.haemochromatosis.org.uk</a></div></li><li class="half_rhythm"><div><b>National Digestive Diseases Information Clearinghouse (NDDIC)</b></div><div>2 Information Way</div><div>Bethesda MD 20892-3570</div><div><b>Phone:</b> 800-891-5389 (toll-free); 866-569-1162 (TTY)</div><div><b>Fax:</b> 703-738-4929</div><div><b>Email:</b> nddic@info.niddk.nih.gov</div><div><a href="https://www.niddk.nih.gov/health-information/liver-disease/hemochromatosis" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hemochromatosis</a></div></li><li class="half_rhythm"><div><b>National Human Genome Research Institute (NHGRI)</b></div><div><a href="http://www.genome.gov/10001214" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Learning About Hereditary Hemochromatosis</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22223/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hereditary hemochromatosis</a></div></li><li class="half_rhythm"><div><b>Iron Disorders Institute (IDI)</b></div><div><b>Phone:</b> 888-565-4766 (Toll-free Information Request Line); 864-292-1175</div><div><b>Email:</b> info@irondisorders.org</div><div><a href="http://www.irondisorders.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.irondisorders.org</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="https://ghr.nlm.nih.gov/condition/hereditary-hemochromatosis" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hereditary hemochromatosis</a></div></li></ul></div><div id="tfr2.Molecular_Genetics"><h2 id="_tfr2_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="tfr2.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>TFR2-Related Hereditary Hemochromatosis: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1349/table/tfr2.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tfr2.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_tfr2.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_tfr2.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_tfr2.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_tfr2.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_tfr2.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_tfr2.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_tfr2.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/7036" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>TFR2</i></a></td><td headers="hd_b_tfr2.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=7036" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">7q22<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_tfr2.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9UP52" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Transferrin receptor protein 2</a></td><td headers="hd_b_tfr2.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/TFR2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TFR2 @ LOVD</a></td><td headers="hd_b_tfr2.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=TFR2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TFR2</a></td><td headers="hd_b_tfr2.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=TFR2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TFR2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="tfr2.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="tfr2.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for TFR2-Related Hereditary Hemochromatosis (<a href="/omim/604250,604720" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1349/table/tfr2.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tfr2.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/604250" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">604250</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HEMOCHROMATOSIS, TYPE 3; HFE3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/604720" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">604720</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">TRANSFERRIN RECEPTOR 2; TFR2</td></tr></tbody></table></div></div><div id="tfr2.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>Iron homeostasis is regulated by the hepcidin pathway. The hepatic peptide hepcidin (encoded by <i>HAMP</i>) is a circulating hormone that regulates the absorption of dietary iron from the duodenum. Hepcidin expression is inappropriately decreased in hereditary hemochromatosis and is abnormally increased in the anemia of chronic diseases. Hepatic proteins essential for normal iron homeostasis, including HFE, transferrin receptor protein 2 (TfR2), and hemojuvelin, function at least in part by modulating the expression of hepcidin [<a class="bk_pop" href="#tfr2.REF.hentze.2010.24">Hentze et al 2010</a>]. Low/absent levels of urinary hepcidin have been reported in <i>TFR2</i>-related hereditary hemochromatosis [<a class="bk_pop" href="#tfr2.REF.nemeth.2005.1803">Nemeth et al 2005</a>], suggesting a mechanism for <i>TFR2-</i>HHC.</p><p><b>Gene structure.</b>
<i>TFR2</i> is 2,471 bp long and consists of 18 exons. There are two main alternatively spliced variants (see <a class="figpopup" href="/books/NBK1349/figure/tfr2.F2/?report=objectonly" target="object" rid-figpopup="figtfr2F2" rid-ob="figobtfr2F2">Figure 2</a>):</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figtfr2F2" co-legend-rid="figlgndtfr2F2"><a href="/books/NBK1349/figure/tfr2.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="figtfr2F2" rid-ob="figobtfr2F2"><img class="small-thumb" src="/books/NBK1349/bin/tfr2-Image002.gif" src-large="/books/NBK1349/bin/tfr2-Image002.jpg" alt="Figure 2. . Schematic representation of TFR2." /></a><div class="icnblk_cntnt" id="figlgndtfr2F2"><h4 id="tfr2.F2"><a href="/books/NBK1349/figure/tfr2.F2/?report=objectonly" target="object" rid-ob="figobtfr2F2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">Schematic representation of <i>TFR2</i>. The two alternatively spliced <i>TFR2</i> transcripts are shown. Transcription start sites of the two <i>TFR2</i> isoforms are indicated by the dotted lines. </p></div></div><ul><li class="half_rhythm"><div>Alpha, corresponding to transcription of all exons. Alpha-<i>TFR2</i> is prevalently and highly expressed in hepatocytes. Two alpha-<i>TFR2</i> cDNAs of 2.9 and 2.3 kb are recognized. The first (Genbank accession <a href="/entrez/viewer.fcgi?db=nuccore&#x00026;id=3135305" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AF053356</a>) lacks 81 nucleotides in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 8 and is 18 nucleotides longer in exon 18 [<a class="bk_pop" href="#tfr2.REF.gl_ckner.1998.1060">Gl&#x000f6;ckner et al 1998</a>] when compared to the second (Genbank accession <a href="/entrez/viewer.fcgi?db=nuccore&#x00026;id=5596369" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AF067864</a>) [<a class="bk_pop" href="#tfr2.REF.kawabata.1999.20826">Kawabata et al 1999</a>].</div></li><li class="half_rhythm"><div>Beta, which has an <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> transcription start site in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 4 [<a class="bk_pop" href="#tfr2.REF.kawabata.1999.20826">Kawabata et al 1999</a>]. Beta-<i>TFR2</i> <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> (<a href="/nuccore/NM_001206855.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001206855.1</a>) lacks exons 1-3 and has 142 additional bases at its 5' end. Beta-<i>TFR2</i> is expressed ubiquitously at very low levels. Based on animal models, it has been proposed that the beta form (<a href="/protein/NP_001193784.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_001193784.1</a>) has a role in regulating iron export in the spleen [<a class="bk_pop" href="#tfr2.REF.roetto.2010.3382">Roetto et al 2010</a>] (see <b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a></b>).</div></li></ul><p><b>Pathogenic variants.</b> Nearly 50 <i>TFR2</i> pathogenic variants have been reported; most are rare or <a class="def" href="/books/n/gene/glossary/def-item/private/">private</a> [<a class="bk_pop" href="#tfr2.REF.radio.2014.83">Radio et al 2014</a>].</p><div id="tfr2.T.tfr2_pathogenic_variants_discusse" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p><i>TFR2</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1349/table/tfr2.T.tfr2_pathogenic_variants_discusse/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__tfr2.T.tfr2_pathogenic_variants_discusse_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_tfr2.T.tfr2_pathogenic_variants_discusse_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_tfr2.T.tfr2_pathogenic_variants_discusse_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_tfr2.T.tfr2_pathogenic_variants_discusse_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_tfr2.T.tfr2_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.88_89dupC<br />(ins88C)</td><td headers="hd_h_tfr2.T.tfr2_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg30ProfsTer31<br />(E60Ter)</td><td headers="hd_h_tfr2.T.tfr2_pathogenic_variants_discusse_1_1_1_3" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?db=nuccore&#x00026;id=110227854" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_003227<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/entrez/viewer.fcgi?db=protein&#x00026;id=33589848" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_003218<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_tfr2.T.tfr2_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.515T&#x0003e;A</td><td headers="hd_h_tfr2.T.tfr2_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Met172Lys</td></tr><tr><td headers="hd_h_tfr2.T.tfr2_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.949C&#x0003e;T</td><td headers="hd_h_tfr2.T.tfr2_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln317Ter</td></tr><tr><td headers="hd_h_tfr2.T.tfr2_pathogenic_variants_discusse_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1861_1872del12</td><td headers="hd_h_tfr2.T.tfr2_pathogenic_variants_discusse_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala621_Gln624del<br />(AVAQ621-624del)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="tfr2.TF.3.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> TfR2 is an 801-amino-acid type II transmembrane glycoprotein characterized by short intracellular and transmembrane domains and a large extracellular <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>. Domains include:</p><ul><li class="half_rhythm"><div>Cytoplasmic <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (1-80aa)</div></li><li class="half_rhythm"><div>Transmembrane <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (81-104aa)</div></li><li class="half_rhythm"><div>Extracellular <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> (105-801aa)</div></li></ul><p>Cysteines 89-98 and 108-111 are involved in disulfide bonds, likely responsible for <i>TFR2</i> homodimerization. A YQRV amino acid motif in the cytoplasmic <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> may be an internalization signal.</p><p>TfR2 is expressed in the liver, especially in the hepatocytes. Recently it has been shown that TfR2 protein is expressed in erythroid cells in mice and humans and that TfR2 protein interacts with the erythropoietin receptor [<a class="bk_pop" href="#tfr2.REF.forejtnikov_.2010.5357">Forejtnikov&#x000e0; et al 2010</a>]. Furthermore, TfR2 alpha protein is expressed in the hippocampal region of mouse brain and seems to be involved in iron accumulation in SNC [<a class="bk_pop" href="#tfr2.REF.pellegrino.2016.30725">Pellegrino et al 2016</a>], whereas beta-Tfr2 isoform is expressed in mouse heart and is involved in cardio-protection against ischemia/reperfusion damage [<a class="bk_pop" href="#tfr2.REF.boero.2015.360">Boero et al 2015</a>].</p><p>Alpha-TfR2 binds and internalizes transferrin. However, binding occurs at low affinity (25- to 30-fold lower) [<a class="bk_pop" href="#tfr2.REF.kawabata.1999.20826">Kawabata et al 1999</a>], as compared to that of the transferrin receptor (TFRC). Alpha-TfR2 protein shows significant amino acid homology with TFRC and the prostate-specific membrane antigen, especially in the extracellular portion [<a class="bk_pop" href="#tfr2.REF.kawabata.1999.20826">Kawabata et al 1999</a>].</p><p>Alpha<i>-TFR2</i> is not transcriptionally regulated by iron. According to the most recent in vitro models TfR2 is able to bind Hfe and Hjv proteins on the cell surface [<a class="bk_pop" href="#tfr2.REF.hentze.2010.24">Hentze et al 2010</a>, <a class="bk_pop" href="#tfr2.REF.dalessio.2012.1052">D'Alessio et al 2012</a>] to regulate hepcidin production.</p><p>Beta-TfR2 lacks the cytoplasmic and transmembrane domains and is an intracellular protein.</p><p>Animal models of the disease have been developed. Tfr2-deficient mouse models show iron overload [<a class="bk_pop" href="#tfr2.REF.roetto.2010.3382">Roetto et al 2010</a>, <a class="bk_pop" href="#tfr2.REF.fleming.2011.117">Fleming et al 2011</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Loss of protein function is associated with disease. The <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> p.Met172Lys is of interest because it causes a <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> in the alpha form but alters methionine, which is the putative initiation codon of beta-<i>TFR2</i> [<a class="bk_pop" href="#tfr2.REF.roetto.2001.2555">Roetto et al 2001</a>, <a class="bk_pop" href="#tfr2.REF.majore.2006.ecr33">Majore et al 2006</a>].</p></div></div><div id="tfr2.References"><h2 id="_tfr2_References_">References</h2><div id="tfr2.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.bacon.2011.328">Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS, et al.  Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. <span><span class="ref-journal">Hepatology. </span>2011;<span class="ref-vol">54</span>:328–43.</span> [<a href="/pmc/articles/PMC3149125/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3149125</span></a>] [<a href="/pubmed/21452290" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21452290</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.badar.2016.420">Badar S, Busti F, Ferrarini A, Xumerle L, Bozzini P, Capelli P, Pozzi-Mucelli R, Campostrini N, De Matteis G, Marin Vargas S, Giorgetti A, Delledonne M, Olivieri O, Girelli D. Identification of novel mutations in hemochromatosis genes by targeted next generation sequencing in Italian patients with unexplained iron overload. <span><span class="ref-journal">Am J Hematol. </span>2016;<span class="ref-vol">91</span>:420–5.</span> [<a href="/pubmed/26799139" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26799139</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.bardoujacquet.2013.278">Bardou-Jacquet E, Cunat S, Beaumont-Epinette MP, Kannengiesser C, Causse X, Sauvion S, Pouliquen B, Deugnier Y, David V, Lor&#x000e9;al O, Aguilar-Martinez P, Brissot P, Jouanolle AM. Variable age of onset and clinical severity in transferrin receptor 2 related haemochromatosis: novel observations. <span><span class="ref-journal">Br J Haematol. </span>2013;<span class="ref-vol">162</span>:278–81.</span> [<a href="/pubmed/23600741" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23600741</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.biasiotto.2008.309">Biasiotto G, Camaschella C, Forni GL, Polotti A, Zecchina G, Arosio P. New TFR2 mutations in young Italian patients with hemochromatosis. <span><span class="ref-journal">Haematologica. </span>2008;<span class="ref-vol">93</span>:309–10.</span> [<a href="/pubmed/18245657" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18245657</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.boero.2015.360">Boero M, Pagliaro P, Tullio F, Pellegrino RM, Palmieri A, Ferbo L, Saglio G, De Gobbi M, Penna C, Roetto A. A comparative study of myocardial molecular phenotypes of two tfr2&#x003b2; null mice: role in ischemia/reperfusion. <span><span class="ref-journal">Biofactors. </span>2015;<span class="ref-vol">41</span>:360–71.</span> [<a href="/pubmed/26458496" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26458496</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.camaschella.2009.140">Camaschella C, Poggiali E. Rare types of genetic hemochromatosis. <span><span class="ref-journal">Acta Haematol. </span>2009;<span class="ref-vol">122</span>:140–5.</span> [<a href="/pubmed/19907151" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19907151</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.dalessio.2012.1052">D'Alessio F, Hentze MW, Muckenthaler MU. The hemochromatosis proteins HFE, TfR2, and HJV form a membrane-associated protein complex for hepcidin regulation. <span><span class="ref-journal">J Hepatol. </span>2012;<span class="ref-vol">57</span>:1052–60.</span> [<a href="/pubmed/22728873" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22728873</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.de_gobbi.2002.973">De Gobbi M, Roetto A, Piperno A, Mariani R, Alberti F, Papanikolaou G, Politou M, Lockitch G, Girelli D, Fargion S, Cox TM, Gasparini P, Cazzola M, Camaschella C. Natural history of juvenile haemochromatosis. <span><span class="ref-journal">Br J Haematol. </span>2002;<span class="ref-vol">117</span>:973–9.</span> [<a href="/pubmed/12060140" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12060140</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.del_castillorueda.2011.68">Del Castillo-Rueda A, Moreno-Carralero MI, Cuadrado-Grande N, M&#x000e9;ndez M, Mor&#x000e1;n-Jim&#x000e9;nez MJ. <span><span class="ref-journal">Med Clin (Barc). </span>2011;<span class="ref-vol">137</span>:68–72.</span> [Hyperferritinemia, ferropenia and metabolic syndrome in a patient with a new mutation of gene TFR2 and another in gene FTL. A family study] [<a href="/pubmed/21524769" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21524769</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.delcastillorueda.2012.15">Del-Castillo-Rueda A, Moreno-Carralero MI, Cuadrado-Grande N, Alvarez-Sala-Walther LA, Enr&#x000ed;quez-de-Salamanca R, M&#x000e9;ndez M, Mor&#x000e1;n-Jim&#x000e9;nez MJ. Mutations in the HFE, TFR2, and SLC40A1 genes in patients with hemochromatosis. <span><span class="ref-journal">Gene. </span>2012;<span class="ref-vol">508</span>:15–20.</span> [<a href="/pubmed/22890139" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22890139</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.european_association_for_the_study_of_the_liver.2010.3">European Association for the Study of the Liver.  EASL clinical practice guidelines for HFE hemochromatosis. <span><span class="ref-journal">J Hepatol. </span>2010;<span class="ref-vol">53</span>:3–22.</span> [<a href="/pubmed/20471131" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20471131</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.faria.2016.10">Faria R, Silva B, Silva C, Loureiro P, Queiroz A, Fraga S, Esteves J, Mendes D, Fleming R, Vieira L, Gon&#x000e7;alves J, Faustino P. Next-generation sequencing of hereditary hemochromatosis-related genes: novel likely pathogenic variants found in the Portuguese population. <span><span class="ref-journal">Blood Cells Mol Dis. </span>2016;<span class="ref-vol">61</span>:10–5.</span> [<a href="/pubmed/27667161" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27667161</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.fleming.2011.117">Fleming RE, Feng Q, Britton RS. Knockout mouse models of iron homeostasis. <span><span class="ref-journal">Annu Rev Nutr. </span>2011;2011;<span class="ref-vol">31</span>:117–37.</span> [<a href="/pubmed/21548776" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21548776</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.forejtnikov_.2010.5357">Forejtnikov&#x000e0; H, Vieillevoye M, Zermati Y, Lambert M, Pellegrino RM, Guihard S, Gaudry M, Camaschella C, Lacombe C, Roetto A, Mayeux P, Verdier F. Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis. <span><span class="ref-journal">Blood. </span>2010;<span class="ref-vol">116</span>:5357–67.</span> [<a href="/pubmed/20826723" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20826723</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.funakoshi.2016.746">Funakoshi N, Chaze I, Alary AS, Tachon G, Cunat S, Giansily-Blaizot M, Bismuth M, Larrey D, Pageaux GP, Schved JF, Donnadieu-Rigole H, Blanc P, Aguilar-Martinez P. The role of genetic factors in patients with hepatocellular carcinoma and iron overload - a prospective series of 234 patients. <span><span class="ref-journal">Liver Int. </span>2016;<span class="ref-vol">36</span>:746–54.</span> [<a href="/pubmed/26474245" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26474245</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.g_rolami.2008.e45">G&#x000e9;rolami V, Le Gac G, Mercier L, Nezri M, Berg&#x000e9;-Lefranc JL, F&#x000e9;rec C. Early-onset haemochromatosis caused by a novel combination of TFR2 mutations (p.R396X/c.1538-2 A&#x0003e;G) in a woman of Italian descent. <span><span class="ref-journal">Haematologica. </span>2008;<span class="ref-vol">93</span>:e45–6.</span> [<a href="/pubmed/18450729" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18450729</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.girelli.2002.1295">Girelli D, Bozzini C, Roetto A, Alberti F, Daraio F, Colombari R, Olivieri O, Corrocher R, Camaschella C. Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene. <span><span class="ref-journal">Gastroenterology. </span>2002;<span class="ref-vol">122</span>:1295–302.</span> [<a href="/pubmed/11984516" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11984516</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.girelli.2011.500">Girelli D, Trombini P, Busti F, Campostrini N, Sandri M, Pelucchi S, Westerman M, Ganz T, Nemeth E, Piperno A, Camaschella C. A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. <span><span class="ref-journal">Haematologica. </span>2011;<span class="ref-vol">96</span>:500–6.</span> [<a href="/pmc/articles/PMC3069225/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3069225</span></a>] [<a href="/pubmed/21173098" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21173098</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.gl_ckner.1998.1060">Gl&#x000f6;ckner G, Scherer S, Schattevoy R, Boright A, Weber J, Tsui LC, Rosenthal A. Large-scale sequencing of two regions in human chromosome 7q22: analysis of 650 kb of genomic sequence around the EPO and CUTL1 loci reveals 17 genes. <span><span class="ref-journal">Genome Res. </span>1998;<span class="ref-vol">8</span>:1060–73.</span> [<a href="/pmc/articles/PMC310788/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC310788</span></a>] [<a href="/pubmed/9799793" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9799793</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.hattori.2012.612">Hattori A, Miyajima H, Tomosugi N, Tatsumi Y, Hayashi H, Wakusawa S. Clinicopathological study of Japanese patients with genetic iron overload syndromes. <span><span class="ref-journal">Pathol Int. </span>2012;<span class="ref-vol">62</span>:612–8.</span> [<a href="/pubmed/22924847" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22924847</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.hayashi.2006.1107">Hayashi H, Wakusawa S, Motonishi S, Miyamoto K, Okada H, Inagaki Y, Ikeda T. Genetic background of primary iron overload syndromes in Japan. <span><span class="ref-journal">Intern Med. </span>2006;<span class="ref-vol">45</span>:1107–11.</span> [<a href="/pubmed/17106152" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17106152</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.hentze.2010.24">Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. <span><span class="ref-journal">Cell. </span>2010;<span class="ref-vol">142</span>:24–38.</span> [<a href="/pubmed/20603012" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20603012</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.hsiao.2007.303">Hsiao PJ, Tsai KB, Shin SJ, Wang CL, Lee ST, Lee JF, Kuo KK. A novel mutation of transferrin receptor 2 in a Taiwanese woman with type 3 hemochromatosis. <span><span class="ref-journal">J Hepatol. </span>2007;<span class="ref-vol">47</span>:303–6.</span> [<a href="/pubmed/17562347" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17562347</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.joshi.2015.221">Joshi R, Shvartsman M, Mor&#x000e1;n E, Lois S, Aranda J, Barqu&#x000e9; A, de la Cruz X, Bruguera M, Vagace JM, Gervasini G, Sanz C, S&#x000e1;nchez M. Functional consequences of transferrin receptor-2 mutations causing hereditary hemochromatosis type 3. <span><span class="ref-journal">Mol Genet Genomic Med. </span>2015;<span class="ref-vol">3</span>:221–32.</span> [<a href="/pmc/articles/PMC4444164/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4444164</span></a>] [<a href="/pubmed/26029709" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26029709</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.kawabata.1999.20826">Kawabata H, Yang R, Hirama T, Vuong PT, Kawano S, Gombart AF, Koeffler HP. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. <span><span class="ref-journal">J Biol Chem. </span>1999;<span class="ref-vol">274</span>:20826–32.</span> [<a href="/pubmed/10409623" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10409623</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.lanktree.2017.228">Lanktree MB, Sadikovic B, Waye JS, Levstik A, Lanktree BB, Yudin J, Crowther MA, Pare G, Adams PC. Clinical evaluation of a hemochromatosis next-generation sequencing gene panel. <span><span class="ref-journal">Eur J Haematol. </span>2017;<span class="ref-vol">98</span>:228–34.</span> [<a href="/pubmed/27753142" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27753142</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.majore.2006.ecr33">Majore S, Milano F, Binni F, Stuppia L, Cerrone A, Tafuri A, De Bernardo C, Palka G, Grammatico P. Homozygous p.M172K mutation of the TFR2 gene in an Italian family with type 3 hereditary hemochromatosis and early onset iron overload. <span><span class="ref-journal">Haematologica. </span>2006;<span class="ref-vol">91</span>:ECR33.</span> [<a href="/pubmed/16923517" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16923517</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.mcdonald.2015.1288">McDonald CJ, Ostini L, Wallace DF, Lyons A, Crawford DH, Subramaniam VN. Next-generation sequencing: application of a novel platform to analyze atypical iron disorders. <span><span class="ref-journal">J Hepatol. </span>2015;<span class="ref-vol">63</span>:1288–93.</span> [<a href="/pubmed/26151776" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26151776</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.nemeth.2005.1803">Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C. Hepcidin is decreased in TFR2-Hemochromatosis. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">105</span>:1803–6.</span> [<a href="/pubmed/15486069" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15486069</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.pellegrino.2016.30725">Pellegrino RM, Boda E, Montarolo F, Boero M, Mezzanotte M, Saglio G, Buffo A, Roetto A. Transferrin receptor 2 dependent alterations of brain iron metabolism affect anxiety circuits in the mouse. <span><span class="ref-journal">Sci Rep. </span>2016;<span class="ref-vol">6</span>:30725.</span> [<a href="/pmc/articles/PMC4967901/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4967901</span></a>] [<a href="/pubmed/27477597" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27477597</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.pelucchi.2009.276">Pelucchi S, Mariani R, Trombini P, Coletti S, Pozzi M, Paolini V, Barisani D, Piperno A. Expression of hepcidin and other iron-related genes in type 3 hemochromatosis due to a novel mutation in transferrin receptor-2. <span><span class="ref-journal">Haematologica. </span>2009;<span class="ref-vol">94</span>:276–9.</span> [<a href="/pmc/articles/PMC2635389/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2635389</span></a>] [<a href="/pubmed/19144662" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19144662</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.peters.2017.56">Peters TM, Meulders AF, Redert K, Cuijpers ML, Rennings AJ, Janssen MC, Blijlevens NM, Swinkels DW. TFR2-related haemochromatosis in the Netherlands: a cause of arthralgia in young adulthood. <span><span class="ref-journal">Neth J Med. </span>2017;<span class="ref-vol">75</span>:56–64.</span> [<a href="/pubmed/28276324" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28276324</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.phatak.2010.1671">Phatak P, Brissot P, Wurster M, Adams PC, Bonkovsky HL, Gross J, Malfertheiner P, McLaren GD, Niederau C, Piperno A, Powell LW, Russo MW, Stoelzel U, Stremmel W, Griffel L, Lynch N, Zhang Y, Pietrangelo A. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:1671–9.</span> [<a href="/pmc/articles/PMC3034044/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3034044</span></a>] [<a href="/pubmed/20814896" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20814896</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.pietrangelo.2005.470">Pietrangelo A, Caleffi A, Henrion J, Ferrara F, Corradini E, Kulaksiz H, Stremmel W, Andreone P, Garuti C. Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. <span><span class="ref-journal">Gastroenterology. </span>2005;<span class="ref-vol">128</span>:470–9.</span> [<a href="/pubmed/15685557" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15685557</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.pietrangelo.2017.1972">Pietrangelo A. The ferroportin disease: pathogenesis, diagnosis and treatment. <span><span class="ref-journal">Haematologica. </span>2017;<span class="ref-vol">102</span>:1972–84.</span> [<a href="/pmc/articles/PMC5709096/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5709096</span></a>] [<a href="/pubmed/29101207" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29101207</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.piperno.2004.359">Piperno A, Roetto A, Mariani R, Pelucchi S, Corengia C, Daraio F, Piga A, Garozzo G, Camaschella C. Homozygosity for transferrin receptor-2 Y250X mutation induces early iron overload. <span><span class="ref-journal">Haematologica. </span>2004;<span class="ref-vol">89</span>:359–60.</span> [<a href="/pubmed/15020277" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15020277</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.piubelli.2017.562">Piubelli C, Castagna A, Marchi G, Rizzi M, Busti F, Badar S, Marchetti M, De Gobbi M, Roetto A, Xumerle L, Suku E, Giorgetti A, Delledonne M, Olivieri O, Girelli D. Identification of new BMP6 pro-peptide mutations in patients with iron overload. <span><span class="ref-journal">Am J Hematol. </span>2017;<span class="ref-vol">92</span>:562–8.</span> [<a href="/pubmed/28335084" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28335084</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.powell.2016.706">Powell LW, Seckington RC, Deugnier Y. Haemochromatosis. <span><span class="ref-journal">Lancet. </span>2016;<span class="ref-vol">388</span>:706–16.</span> [<a href="/pubmed/26975792" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26975792</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.radio.2014.83">Radio FC, Majore S, Binni F, Valiante M, Ricerca BM, De Bernardo C, Morrone A, Grammatico P. TFR2-related hereditary hemochromatosis as a frequent cause of primary iron overload in patients from Central-Southern Italy. <span><span class="ref-journal">Blood Cells Mol Dis. </span>2014;<span class="ref-vol">52</span>:83–7.</span> [<a href="/pubmed/24055163" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24055163</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.ravasi.2015.e226">Ravasi G, Rausa M, Pelucchi S, Arosio C, Greni F, Mariani R, Pelloni I, Silvestri L, Pineda P, Camaschella C, Piperno A. Transferrin receptor 2 mutations in patients with juvenile hemochromatosis phenotype. <span><span class="ref-journal">Am J Hematol. </span>2015;<span class="ref-vol">90</span>:E226–7.</span> [<a href="/pubmed/26408288" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26408288</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.ricerca.2009.494">Ricerca BM, Radio FC, De Marinis L, De Bernardo C, Castori M, Sacco E, Grammatico P, Majore S. Natural history of TFR2-related hereditary hemochromatosis in a 47-yr-old Italian patient. <span><span class="ref-journal">Eur J Haematol. </span>2009;<span class="ref-vol">83</span>:494–6.</span> [<a href="/pubmed/19549277" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19549277</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.riva.2004.370">Riva A, Mariani R, Bovo G, Pelucchi S, Arosio C, Salvioni A, Vergani A, Piperno A. Type 3 hemochromatosis and beta-thalassemia trait. <span><span class="ref-journal">Eur J Haematol. </span>2004;<span class="ref-vol">72</span>:370–4.</span> [<a href="/pubmed/15059075" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15059075</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.roetto.2010.3382">Roetto A, Di Cunto F, Pellegrino RM, Hirsch E, Azzolino O, Bondi A, Defilippi I, Carturan S, Miniscalco B, Riondato F, Cilloni D, Silengo L, Altruda F, Camaschella C, Saglio G. Comparison of 3 Tfr2-deficient murine models suggests distinct functions for Tfr2-alpha and Tfr2-beta isoforms in different tissues. <span><span class="ref-journal">Blood. </span>2010;<span class="ref-vol">115</span>:3382–9.</span> [<a href="/pubmed/20179178" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20179178</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.roetto.2001.2555">Roetto A, Totaro A, Piperno A, Piga A, Longo F, Garozzo G, Cali A, De Gobbi M, Gasparini P, Camaschella C. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. <span><span class="ref-journal">Blood. </span>2001;<span class="ref-vol">97</span>:2555–60.</span> [<a href="/pubmed/11313241" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11313241</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.tauchenov_.2016.1574.e1">Tauchenov&#x000e1; L, K&#x00159;&#x000ed;&#x0017e;ov&#x000e1; B, Kub&#x000e1;nek M, Fra&#x00148;kov&#x000e1; S, Melenovsk&#x000fd; V, Tint&#x0011b;ra J, Kautznerov&#x000e1; D, Malu&#x00161;kov&#x000e1; J, Jirsa M, Kautzner J. Successful treatment of iron-overload cardiomyopathy in hereditary hemochromatosis with deferoxamine and deferiprone. <span><span class="ref-journal">Can J Cardiol. </span>2016;<span class="ref-vol">32</span>:1574.e1–1574.e3.</span> [<a href="/pubmed/27789107" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27789107</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.wallace.2016.618">Wallace DF, Subramaniam VN. The global prevalence of HFE and non-HFE hemochromatosis estimated from analysis of next-generation sequencing data. <span><span class="ref-journal">Genet Med. </span>2016;<span class="ref-vol">18</span>:618–26.</span> [<a href="/pubmed/26633544" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26633544</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.wang.2017.521">Wang Y, Du Y, Liu G, Guo S, Hou B, Jiang X, Han B, Chang Y, Nie G. Identification of novel mutations in HFE, HFE2, TfR2, and SLC40A1 genes in Chinese patients affected by hereditary hemochromatosis. <span><span class="ref-journal">Int J Hematol. </span>2017;<span class="ref-vol">105</span>:521–5.</span> [<a href="/pubmed/27896572" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27896572</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="tfr2.REF.zoller.2016.364">Zoller H, Henninger B. Pathogenesis, diagnosis and treatment of hemochromatosis. <span><span class="ref-journal">Dig Dis. </span>2016;<span class="ref-vol">34</span>:364–73.</span> [<a href="/pubmed/27170390" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27170390</span></a>]</div></li></ul></div></div><div id="tfr2.Chapter_Notes"><h2 id="_tfr2_Chapter_Notes_">Chapter Notes</h2><div id="tfr2.Author_History"><h3>Author History</h3><p>Clara Camaschella, MD; Istituto Scientifico San Raffaele (2005-2018)<br />Marco De Gobbi, MD (2018-present)<br />Antonella Roetto, PhD (2005-present)</p></div><div id="tfr2.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>15 February 2018 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>9 June 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>5 August 2008 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> available clinically</div></li><li class="half_rhythm"><div>15 May 2008 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 August 2006 (ar) Revision: change in mutation nomenclature from AVAQ594-597del to AVAQ621-624del</div></li><li class="half_rhythm"><div>5 December 2005 (ar) Revision: <a class="def" href="/books/n/gene/glossary/def-item/targeted-mutation-analysis/">targeted mutation analysis</a> clinically available; mutation scanning no longer available</div></li><li class="half_rhythm"><div>29 August 2005 (me) Review posted live</div></li><li class="half_rhythm"><div>1 February 2005 (ar) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1349</span><span class="label">PMID: <a href="/pubmed/20301523" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301523</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/tbc1d24-dis/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/tk2-mtddepl/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1349&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1349/?report=reader">PubReader</a></li><li><a href="/books/NBK1349/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1349" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1349" style="display:none" title="Cite this Page"><div class="bk_tt">De Gobbi M, Roetto A. TFR2-Related Hereditary Hemochromatosis. 2005 Aug 29 [Updated 2018 Feb 15]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1349/pdf/Bookshelf_NBK1349.pdf">PDF version of this page</a> (764K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#tfr2.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#tfr2.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#tfr2.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#tfr2.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#tfr2.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#tfr2.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#tfr2.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#tfr2.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#tfr2.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#tfr2.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#tfr2.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=7036[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">TFR2</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1349+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1476944" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1476944" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1476944" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1476944" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301613" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">HFE</i> Hemochromatosis</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">HFE</i> Hemochromatosis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Barton JC, Edwards CQ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301349" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Juvenile Hereditary Hemochromatosis</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Juvenile Hereditary Hemochromatosis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Goldberg YP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301599" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Beta-Thalassemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Beta-Thalassemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Origa R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24624460" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">EPB42</i>-Related Hereditary Spherocytosis</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">EPB42</i>-Related Hereditary Spherocytosis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kalfa TA, Connor JA, Begtrup AH. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301666" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Aceruloplasminemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Aceruloplasminemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Miyajima H, Hosoi Y. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301523" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301523" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e042b7275f66d18aa1c9bcd">TFR2-Related Hereditary Hemochromatosis - GeneReviews®</a><div class="ralinkpop offscreen_noflow">TFR2-Related Hereditary Hemochromatosis - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T22:39:30-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8AFAF2E04291D10000000000FC005F&amp;ncbi_session=CE8AFAF2E042B721_0252SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1349%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1349&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1349/&amp;ncbi_pagename=TFR2-Related Hereditary Hemochromatosis - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8AFAF2E042B721_0252SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>